Quick Answer
Intellia Therapeutics, Inc. reported Research And Development Expense of $388.86 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed a decrease of -16.6% in Research And Development Expense from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Research And Development Expense has grown by 3,381.3%.
- Historical annual values: Fiscal year 2025: $388.86 million | Fiscal year 2024: $466.31 million | Fiscal year 2023: $435.07 million | Fiscal year 2022: $419.98 million | Fiscal year 2021: $229.81 million | Fiscal year 2020: $150.41 million | Fiscal year 2019: $108.41 million | Fiscal year 2018: $89.12 million | Fiscal year 2017: $67.65 million | Fiscal year 2016: $31.84 million | Fiscal year 2015: $11.17 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: